DOI QR코드

DOI QR Code

Meta-analysis of the Relation Between the VDR Gene TaqIpolymorphism and Genetic Susceptibility to Prostate Cancer in Asian Populations

  • Guo, Ya-Jie ;
  • Shi, Ze-Ming ;
  • Liu, Jun-Da ;
  • Lei, Ning ;
  • Chen, Qiu-Hong ;
  • Tang, Ying
  • Published : 2012.09.30

Abstract

Background: Polymorphisms of the Taq I gene have been associated with prostate cancer risk. Methods:We applied a fixed-effects model to combine odds ratios (ORs) and 95% confidence intervals (95% CI). The Egger's test was carried out to evaluate potential publication bias. Results: A total of 10 case-control studies enrolling 1,141 prostate cancer patients and 1,685 controls were included in this meta-analysis. Compared with the T allele, the OR for the C allele was 0.81 (0.70-0.94). The ORs for CT and CC+CT genotypes were 0.86 (0.74-1.01) and 0.84 (0.73-0.97) compared to wide type genotype (homozygote TT). Conclusions: The present meta-analysis suggests that the TF gene Taq I polymorphism may reduce the prostate cancer risk in Asian populations.

Keywords

Vitamin D receptor;Taq I;prostate cancer;Asian populations;meta-analysis

References

  1. Bao BY, Yeh SD, Lee YF (2006). 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases.Carcinogenesis, 27, 32-42.
  2. Bai Y, Yu Y, Yu B, et al (2009). Association of vitamin D receptor polymorphisms with the risk of prostate cancer in the Han population of Southern China. BMC Med Genet, 10, 125.
  3. Bid HK, Mishra DK, Mittal RD (2005). Vitamin-D receptor (VDR) gene (Fok-I, Taq-I and Apa-I) polymorphisms in healthy individuals from north Indian population. Asian Pac J Cancer Pre, 6, 147-52.
  4. Campbell MJ, Elstner E, Holden S, et al (1997). Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and Ecadherin. J Mol Endocrinol, 19, 15-27. https://doi.org/10.1677/jme.0.0190015
  5. Cariati F, Negri A, Pivonello C, et al (2012). Vitamin D from genetics to the clinical in prostate cancer. Endocrine Abstracts, 29, P836.
  6. Chaimuangraj S, Thammachoti R, Ongphiphadhanakul B, et al (2006). Lack of association of VDR polymorphisms with Thai prostate cancer as compared with benign prostate hyperplasia and controls. Asian Pac J Cancer Prev, 7, 136-9.
  7. Corder EH, Guess HA, Hulka BS et al (1993).Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev, 2, 467-72.
  8. Dersimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  9. Habuchi T, Suzuki T, Sasaki R, et al (2000). Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res, 60, 305-8.
  10. Hamasaki T, Inatomi H, Katoh T, et al (2001).Clinical and pathological significance of vitamin D receptor gene polymorphism for prostate cancer which is associated with a higher mortality in Japanese. Endocr J, 48, 543-9. https://doi.org/10.1507/endocrj.48.543
  11. Hamasaki T, Inatomi H, Katoh T, et al (2002). Significance of vitamin D receptor gene polymorphism for risk and disease severity of prostate cancer and benign prostatic hyperplasia in Japanese. Urol Int, 68, 226-31. https://doi.org/10.1159/000058440
  12. Hidalgo AA, Paredes R, Garcia VM, et al (2007). Altered VDRmediated transcriptional activity in prostate cancer stroma. J Steroid Biochem Mol Biol, 103, 731-6. https://doi.org/10.1016/j.jsbmb.2006.12.072
  13. Huang SP, Chou YH, Wayne Chang WS, et al (2004).Association between vitamin D receptor polymorphisms and prostate cancer risk in a Taiwanese population. Cancer Lett, 207, 69-77. https://doi.org/10.1016/j.canlet.2003.12.006
  14. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49. https://doi.org/10.3322/caac.20006
  15. Jose S, George PS, Mathew A (2008). Assessment of confounding and interaction using the mantel-haenszel risk estimation method. Asian Pac J Cancer Prev, 9, 323-5.
  16. Krishnan AV, Peehl DM, Feldman D (2003). Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem, 88, 363-71. https://doi.org/10.1002/jcb.10334
  17. Li M, Zhang S, Ma J, et al (2009). A comparative study on incidence trends of prostate cancer in part of cities and counties in China. Chin J Urol, 30, 368-70. (article in China)
  18. Liu J, Li H, Gu L, et al (2004a). Association between VDRG 3' polymorphisms and prostate cancer in Chinese population. Chin J Clin Rehab, 8, 3429-32. (article in China)
  19. Liu J, Li H, Tong M, et al (2004b). Susceptibility gene polymorphism and risk of prostate cancer in Chinese population. Nat Med J China, 84, 364-8. (article in China)
  20. Moon SJ, Fryer AA, Strange RC (2005). Ultraviolet radiation: effects on risks of prostate cancer and other internal cancers. Mutat Res, 571, 207-19. https://doi.org/10.1016/j.mrfmmm.2004.09.015
  21. Onsory K, Sobti RC, Al-Badran AI, et al (2008). Hormone receptor-related gene polymorphisms and prostate cancer risk in North Indian population.Mol Cell Biochem,314,25-35. https://doi.org/10.1007/s11010-008-9761-1
  22. Schaid DJ(2004).The complex genetic epidemiology of prostate cancer. Hum Mol Genet, 13, R103-21. https://doi.org/10.1093/hmg/ddh072
  23. Schwartz GG (2012). Circulating vitamin D and risk of prostate cancer--letter. Cancer Epidemiol Biomarkers Prev, 21, 246. https://doi.org/10.1158/1055-9965.EPI-11-0910
  24. Schwartz GG, Hulka BS (1990). Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res, 10, 1307-11.
  25. Suzuki K, Matsui H, Ohtake N, et al (2003).Vitamin D receptor gene polymorphism in familial prostate cancer in a Japanese population. Int J Urol, 10, 261-6. https://doi.org/10.1046/j.1442-2042.2003.00617.x
  26. Vieira AR (2006). Association between the transforming growth factor alpha gene and nonsyndromic oral clefts: a HuGE review. Am J Epidemiol, 163, 790-810. https://doi.org/10.1093/aje/kwj103
  27. Watanabe M, Fukutome K, Murata M, et al (1999).Significance of vitamin D receptor gene polymorphism for prostate cancer risk in Japanese. Anticancer Res, 19, 4511-4.
  28. Williamson PR, Gamble C, Altman DG, et al (2005). Outcome selection bias in meta-analysis. Stat Methods Med Res, 14, 515-24. https://doi.org/10.1191/0962280205sm415oa
  29. Ylikomi T, Laaksi I, Lou YR, et al (2002).Antiproliferative action of vitamin D. Vitam Horm, 64, 357-406. https://doi.org/10.1016/S0083-6729(02)64010-5
  30. Zhang WB, Zhang JH, Pan ZQ, et al (2012). The MTHFR C677T Polymorphism and Prostate Cancer Risk: New Findings from a Meta-analysis of 7306 Cases and 8062 Controls. Asian Pac J Cancer Prev, 13, 2597-604. https://doi.org/10.7314/APJCP.2012.13.6.2597
  31. Zmuda JM, Cauley JA, Ferrell RE (2000).Molecular epidemiology of vitamin D receptor gene variants. Epidemiol Rev, 22, 203-17. https://doi.org/10.1093/oxfordjournals.epirev.a018033

Cited by

  1. Association of Benign Prostate Hyperplasia with Polymorphisms in VDR, CYP17, and SRD5A2 Genes among Lebanese Men vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1255
  2. An Integrated Approach to Defining Genetic and Environmental Determinants for Major Clinical Outcomes Involving Vitamin D vol.18, pp.3, 2014, https://doi.org/10.1007/s40291-014-0087-2
  3. Systematic review and meta-analysis on vitamin D receptor polymorphisms and cancer risk vol.35, pp.5, 2014, https://doi.org/10.1007/s13277-013-1544-y
  4. The Effects of Various Chemical Factors on Prostate Tumor Cells of Cx43 and the Significance of the Cancer Treatment vol.05, pp.01, 2015, https://doi.org/10.12677/WJCR.2015.51002